Arzerra Gets a New Boxed Warning Legal Examiner The anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) recently got an upgrade to their boxed warning labels, adding information about the potential risk for reactivation of hepatitis B infection, in patients who have previously suffered ... |
